Buscar
Mostrando ítems 21-30 de 103
Serum Potassium Dynamics During Acute Heart Failure Hospitalization
(Springer, 2020-10-17)
[Abstract]
Background.
Available information about prognostic implications of potassium levels alteration in the setting of acute heart failure (AHF) is scarce.
Objectives.
We aim to describe the prevalence of ...
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
(Wolters Kluwer, 2020-07)
[Abstract]
Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart ...
Spanish Heart Transplant Registry: 31th Official Report of the Heart Failure Association of the Spanish Society of Cardiology
(Elsevier, 2020-08-14)
[Abstract]
Introduction and objectives.
The present report describes the clinical characteristics and outcomes of heart transplants in Spain and updates the data to 2019.
Methods.
We describe the clinical characteristics ...
Cardiac Protection Induced by Urocortin-2 Enables the Regulation of Apoptosis and Fibrosis After Ischemia and Reperfusion Involving miR-29a Modulation
(Elsevier, 2022-01-28)
[Abstract] Urocortin-2 (Ucn-2) has demonstrated cardioprotective actions against myocardial ischemia-reperfusion (I/R) injuries. Herein, we explored the protective role of Ucn-2 through microRNAs (miRNAs) post-transcriptional ...
Diagnostic and Prognostic Value of Cardiac Imaging in Amyloidosis
(Baishideng Publishing Group Inc., 2020-12-26)
[Abstract]
Amyloidosis is an infiltrative disease caused by extracellular protein deposition
that has accumulated a lot of scientific production in recent years. Different types
of amyloidosis can affect the heart. ...
Light Chain and Transthyretin Cardiac Amyloidosis: Clinical Characteristics, Natural History and Prognostic Factors
(Elsevier, 2021-03-13)
[Abstract]
Introduction and objectives.
Light-chain amyloidosis (AL-CA) and transthyretin amyloidosis (ATTR-CA) are the most common types of cardiac amyloidosis (CA). We sought to study the clinical characteristics and ...
Heart Failure Association of the European Society of Cardiology Position Paper on the Management of Left Ventricular Assist Device-Supported Patients for the Non-left Ventricular Assist Device Specialist Healthcare Provider: Part 2: At the Emergency Department
(Wiley, 2021-09-14)
[Abstract] The improvement in left ventricular assist device (LVAD) technology and scarcity of donor hearts have increased dramatically the population of the LVAD-supported patients and the probability of those patients ...
HFA of the ESC Position Paper on the Management of LVAD Supported Patients for the non LVAD Specialist Healthcare Provider Part 1: Introduction and at the Non-hospital Settings in the Community
(Wiley, 2021-09-14)
[Abstract] The accepted use of left ventricular assist device (LVAD) technology as a good alternative for the treatment of patients with advanced heart failure together with the improved survival of the LVAD-supported ...
Guidance on the Management of Left Ventricular Assist Device (LVAD) Supported Patients for the Non-LVAD Specialist Healthcare Provider: Executive Summary
(Wiley, 2021-08-18)
[Abstract] The accepted use of left ventricular assist device (LVAD) technology as a good alternative for the treatment of patients with advanced heart failure together with the improved survival of patients on the device ...
Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data From 9222 Chronic Heart Failure Patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
(Willey Online Library, 2020-04-03)
[Abstract]
Aims.
We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death ...